-+ 0.00%
-+ 0.00%
-+ 0.00%

Changes in Hong Kong stocks | Goli Pharmaceutical-B (01672) rose nearly 5% in early trading, the company launched ASC36 oral tablet US phase I obesity study

Zhitongcaijing·09/10/2026 01:33:02
Listen to the news

The Zhitong Finance App learned that Goli Pharmaceutical-B (01672) rose nearly 5% in early trading. As of press release, it rose 4.97% to HK$10.56, with a turnover of HK$85,400.

According to the news, Cully Pharmaceuticals announced that after receiving approval from the US Food and Drug Administration (FDA) for a new drug clinical trial (IND), it has initiated a US phase I study on the use of ASC36 oral tablets (oral pancreatic agonist polypeptides) to treat obesity.

Dr. Wu Jinzi, founder, chairman of the board of directors and CEO of Goli, said that in 2026, we started four Phase I studies on the peptide pipeline. ASC36 oral tablets are the fourth and latest of them. This is an important milestone in the Geli peptide pipeline and further validates our proprietary POTENT oral peptide delivery technology.